Bluebee raises €1.75 million to bring supercomputing to genomics
Bluebee announced a pre-equity round of 1.75 million EUR (1.90 million USD) from investment firm Buysse & Partners and existing shareholder Delft University of Technology to bring its cloud-based, accelerated genomics solution to clinicians and labs. Bluebee’s technology, based on hybrid-core computing (FPGA) allows clinicians to shorten the time-to-diagnosis substantially.
Founded in 2011 as a spin-off of the Delft University of Technology and Imperial College London, Bluebee offers a cloud-based, distributed computing solution combined with accelerated hardware. This allows mass sequencing data volumes to be processed in extremely short timeframes.
“Time-to-diagnosis is crucial for patients and can mean the difference between life and death, a notable example being neonatal cancer patients where every day counts." says Hans Cobben, CEO of Bluebee. “But beyond that, moving one step closer to truly targeted medicine will prove to be a game changer for the medical as well as the pharmaceutical industry. Innovative technologies in genetic screening and analytics will enable the introduction of completely new diagnostics and therapies in healthcare.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
